RemeGen’s telitacicept won a key efficacy signal in an interim analysis of a Phase 3 trial for high-risk IgA nephropathy. Presented in a NEJM report, the study found that 39 weeks of once-weekly subcutaneous telitacicept (240 mg) drove a substantially larger reduction in urine protein-to-creatinine ratios than placebo. Among 318 enrolled patients, the 24-hour urine protein-to-creatinine ratio fell 58.9% with telitacicept versus 8.8% with placebo at week 39, corresponding to a relative difference of -55.0% (95% CI, -61.3 to -47.6; P<0.001). Estimated glomerular filtration rate changes were smaller in both groups, with no unexpected safety findings reported. Adverse events were more frequent on telitacicept (89.3% vs. 78.6%); serious adverse events were lower (2.5% vs. 8.2%). The trial is registered as NCT05799287.